Compare Nu Holdings Ltd (NU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Nu Holdings Ltd trades at $13.6 (market cap $65.94B), while Sana Biotechnology Inc trades at $3.85 (market cap $1.13B). The key difference: Nu Holdings Ltd is far larger — about 58.4× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| NU | SANA | |
|---|---|---|
Market Cap | $65.94B | $1.13B |
Sector | Financials | Health |
52-Week High | $18.76 | $5.92 |
52-Week Low | $11.60 | $2.68 |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $13.615, down 1.77% on the day, amid bearish technical signals but strong fundamentals. Revenue grew from $3.0B in 2022 to $10.63B in 2025, with net income turning positive to $2.87B. The company recently announced a Brazilian banking license acquisition (PYMNTS, 2026-07-22), supporting expansion. Analysts maintain a buy consensus with a $14.98 target, though recent earnings misses and competitive pressures pose headwinds.
Outlook: NU's robust growth trajectory and high ROE (30.04% as of 2025) offer upside, but technical weakness and Latin American market risks require caution. The Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) is a key catalyst, with expectations of $0.1984 EPS. Investors should weigh strong profitability against bearish momentum and rising competition.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
